Auris Medical Holding AG (EARS):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Auris Medical Holding AG (EARS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9779
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:48
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スイス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Auris Medical Holding AG (Auris Medical) is a clinical-stage biopharmaceutical company with focus on neurotology and mental health supportive care. The company’s pipeline product candidates are in various clinical phases intended for the treatment of acute inner ear tinnitus, post-acute inner ear tinnitus, tinnitus, Meniere’s disease (Vertigo), sudden loss of hearing, antipsychotic-induced weight gain and somnolence. It has research collaboration and licensing agreements with research institutions such as King’s College London and pharmaceutical and biotechnology companies including Xigen and Inserm. Auris Medical is headquartered in Zug, Switzerland.

Auris Medical Holding AG (EARS) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Auris Medical Holding AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Auris Medical Holding AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Auris Medical Holding AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Auris Medical Holding AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Auris Medical Holding AG, Medical Devices Deals, 2012 to YTD 2018 10
Auris Medical Holding AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Auris Medical Holding AG, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Auris Medical Acquires Intranasal Betahistine from Otifex Therapeutics 12
Venture Financing 13
Auris Medical Raises US$51 Million In Series C Financing 13
Partnerships 15
Auris Medical Extends its Drug Discovery Agreement with King’s College 15
Auris Medical Enters Into Agreement With Medidata Solutions 16
Equity Offering 17
Auris Medical Raises USD7 Million in Public Offering of Shares 17
Auris Medical to Raise Funds through Public Offering of shares 18
Auris Medical Raises USD5.5 Million in Public Offering of Shares 19
Auris Medical Raises USD10 Million in Public Offering of Units 20
Auris Medical to Raise up to USD35 Million in Public Offering of Shares 22
Auris Medical Raises USD25 Million in Public Offering of Shares 23
Auris Medical Completes Underwriters Partial Exercise of Over-Allotment Option of IPO for USD60.7 Million 24
Auris Medical Holding AG – Key Competitors 26
Auris Medical Holding AG – Key Employees 27
Auris Medical Holding AG – Locations And Subsidiaries 28
Head Office 28
Other Locations & Subsidiaries 28
Recent Developments 29
Financial Announcements 29
Aug 15, 2018: Auris Medical announces second quarter 2018 financial results 29
May 15, 2018: Auris Medical Provides Business and Strategy Update and Reports First Quarter 2018 Financial Results 31
Mar 22, 2018: Auris Medical Provides Business Update and Reports Fourth Quarter and Full Year 2017 Financial Results 33
Nov 28, 2017: Auris Medical Reports Third Quarter 2017 Financial Results and Provides Business Update 35
Aug 10, 2017: Auris Medical Provides Business Update and Reports Second Quarter 2017 Financial Results 37
May 11, 2017: Auris Medical Provides Business Update and Reports First Quarter 2017 Financial Results 39
Mar 14, 2017: Auris Medical Provides Business Update and Reports Full Year 2016 Financial Results 41
Corporate Communications 43
Sep 26, 2017: Auris Medical Provides Board of Directors Update 43
Product News 44
05/30/2018: Auris Medical to Host Key Opinion Leader Call Focused on AM-201 Program for Treating Major Side Effects of Antipsychotics on June 11, 2018 44
Mar 16, 2018: Auris’ tinnitus treatment fails late-stage study for the second time 45
02/03/2017: Auris Medical Expands Clinical Development Pipeline with Intranasal Betahistine for the Treatment of Meniere’s Disease and Vestibular Vertigo 46
Clinical Trials 47
Feb 07, 2018: Auris Medical Reports New Data Highlighting Superior Bioavailability of AM-125 Compared to Oral Betahistine 47
Appendix 48
Methodology 48
About GlobalData 48
Contact Us 48
Disclaimer 48

List of Tables
Auris Medical Holding AG, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Auris Medical Holding AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Auris Medical Holding AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Auris Medical Holding AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Auris Medical Holding AG, Deals By Therapy Area, 2012 to YTD 2018 9
Auris Medical Holding AG, Medical Devices Deals, 2012 to YTD 2018 10
Auris Medical Holding AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Auris Medical Acquires Intranasal Betahistine from Otifex Therapeutics 12
Auris Medical Raises US$51 Million In Series C Financing 13
Auris Medical Extends its Drug Discovery Agreement with King's College 15
Auris Medical Enters Into Agreement With Medidata Solutions 16
Auris Medical Raises USD7 Million in Public Offering of Shares 17
Auris Medical to Raise Funds through Public Offering of shares 18
Auris Medical Raises USD5.5 Million in Public Offering of Shares 19
Auris Medical Raises USD10 Million in Public Offering of Units 20
Auris Medical to Raise up to USD35 Million in Public Offering of Shares 22
Auris Medical Raises USD25 Million in Public Offering of Shares 23
Auris Medical Completes Underwriters Partial Exercise of Over-Allotment Option of IPO for USD60.7 Million 24
Auris Medical Holding AG, Key Competitors 26
Auris Medical Holding AG, Key Employees 27
Auris Medical Holding AG, Subsidiaries 28

List of Figures
Auris Medical Holding AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Auris Medical Holding AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Auris Medical Holding AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Auris Medical Holding AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Auris Medical Holding AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Auris Medical Holding AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Auris Medical Holding AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Auris Medical Holding AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Auris Medical Holding AG, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Auris Medical Holding AG (EARS):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • JX Nippon Oil & Energy Corporation-エネルギー分野:企業M&A・提携分析
    Summary JX Nippon Oil & Energy Corporation (JXNOE) is a downstream refining company. The company refines and markets petroleum and petrochemical products. Its products include petrochemicals, lubricants, optical films, greases, fluids, engine oils, composites, Panaferd-AX, Tow PREPREG, sheet pallet …
  • Danfoss AS:企業の戦略的SWOT分析
    Danfoss AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • Scorpio Tankers Inc (STNG):石油・ガス:M&Aディール及び事業提携情報
    Summary Scorpio Tankers Inc. (Scorpio Tankers), a part of Scorpio Group, provides marine transportation of refined petroleum products and crude oil worldwide. The company operates through a network of owned and time chartered vessels, which distribute vegetable oils, petroleum-based feedstock and re …
  • Banca Monte dei Paschi di Siena SpA:企業のM&A・事業提携・投資動向
    Banca Monte dei Paschi di Siena SpA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Banca Monte dei Paschi di Siena SpA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on …
  • Pirelli & C. S.p.A.:企業の戦略・SWOT・財務情報
    Pirelli & C. S.p.A. - Strategy, SWOT and Corporate Finance Report Summary Pirelli & C. S.p.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • UGL Ltd:企業の戦略的SWOT分析
    UGL Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …
  • FirstRand Private Bank:企業の戦略・SWOT・財務情報
    FirstRand Private Bank - Strategy, SWOT and Corporate Finance Report Summary FirstRand Private Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Lotte Holdings Co. Ltd.:企業の戦略・SWOT・財務情報
    Lotte Holdings Co. Ltd. - Strategy, SWOT and Corporate Finance Report Summary Lotte Holdings Co. Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Bilim Pharmaceuticals:企業の戦略的SWOT分析
    Bilim Pharmaceuticals - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Restaurant Brands New Zealand Limited:企業の戦略・SWOT・財務分析
    Restaurant Brands New Zealand Limited - Strategy, SWOT and Corporate Finance Report Summary Restaurant Brands New Zealand Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • LifeVantage Corp (LFVN):企業の財務・戦略的SWOT分析
    Summary LifeVantage Corp (LifeVantage) is a science-based nutraceutical company that manufactures and markets dietary supplements. The company offers products such as protandim, axio, physiq, truescience and canine health, among others. Its beauty products include cleansers, hand creams, micro lift, …
  • Weifa ASA (WEIFA)-製薬・医療分野:企業M&A・提携分析
    Summary Weifa ASA (Weifa), formerly Aqualis ASA, is a pharmaceutical company that conducts the research and development, manufacture, distribution and sales of pharmaceutical products, lifestyle products and solutions. The company has over the counter (OTC) pharmaceutical market in Norway offering p …
  • The Arab Assurers Insurance Co.:企業の戦略・SWOT・財務情報
    The Arab Assurers Insurance Co. - Strategy, SWOT and Corporate Finance Report Summary The Arab Assurers Insurance Co. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Apple Inc:企業の戦略・SWOT・財務分析
    Apple Inc - Strategy, SWOT and Corporate Finance Report Summary Apple Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Ubiquiti Networks Inc:企業の戦略・SWOT・財務分析
    Ubiquiti Networks Inc - Strategy, SWOT and Corporate Finance Report Summary Ubiquiti Networks Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Tokyo Gas Co Ltd (9531)-エネルギー分野:企業M&A・提携分析
    Summary Tokyo Gas Co Ltd (Tokyo Gas) is a gas utility that produces, supplies and markets liquefied natural gas (LNG). It also produces, supplies and sells electricity. Tokyo Gas also has overseas upstream, midstream and downstream businesses. It provides engineering solutions, gas appliances and ga …
  • BrightPath Early Learning Inc.:企業の戦略的SWOT分析
    BrightPath Early Learning Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • Louisiana-Pacific Corporation:戦略・SWOT・企業財務分析
    Louisiana-Pacific Corporation - Strategy, SWOT and Corporate Finance Report Summary Louisiana-Pacific Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Midea Group Co Ltd:企業の戦略・SWOT・財務分析
    Midea Group Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Midea Group Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Aarhus University-製薬・医療分野:企業M&A・提携分析
    Summary Aarhus University (Aarhus) is a university that undertakes activities related to research, talent development, knowledge exchange and education. The university offers bachelor’s degree programmes, master’s degree programmes and PhD programmes in various disciplines. Its areas of academic int …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆